Abstract
Figures and Tables
Table 1
FMD, foot-and-mouth disease; SP, structural proteins; NSP, nonstructural proteins; CB, Chungbuk; CN, Chungnam; GG, Gyeonggi; GB, Gyenogbuk; GW, Gangwon; SJ, Sejong city; IC, Incheon city; GN, Gyenognam; ND, not done. *Diagnosis by real-time polymerase chain reaction, antigen enzyme-linked immunosorbent assay, or lateral-flow assay. †Percentage antibody prevalence (No. of positive/No. of tested). ‡Mean antibody prevalence (positive rate) in Korea, December 2014.
Table 2
FMDV, foot-and-mouth disease virus; FMD, foot-and-mouth disease; SEA, South-East Asia; ME-SA, Middle East and South Asia; NA, not available; -, not tested. *Values were calculated by division between the viral titers (serum titer against viruses used for cross virus neutralization test/serum titer against vaccine viruses in the vaccination groups). †Tested by World Reference Laboratory for FMD (Pirbright Institute), UK except an indication note. ‡Tested by MSD Animal Health (FMD vaccine manufacturer). §Tested by Merial Boehringer Ingelheim (FMD vaccine manufacturer). ∥Tested by World Organisation for Animal Health (OIE) Regional Reference Laboratory for FMD (ARRIAH), Russia. ¶Tested by OIE Reference Laboratory for FMD (SENASA), Argentina.